Abstract
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4CD25 T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antigens, CD
-
Antigens, Differentiation / immunology*
-
Autoimmune Diseases / blood
-
Autoimmune Diseases / chemically induced*
-
Autoimmune Diseases / pathology
-
Autoimmune Diseases / therapy
-
CTLA-4 Antigen
-
Carcinoma, Renal Cell / drug therapy
-
Carcinoma, Renal Cell / secondary
-
Humans
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / pathology
-
Magnetic Resonance Imaging
-
Male
-
Melanoma / drug therapy
-
Melanoma / secondary
-
Middle Aged
-
Neoplasm Metastasis
-
Pituitary Gland / drug effects*
-
Pituitary Gland / pathology
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, Differentiation
-
CTLA-4 Antigen
-
CTLA4 protein, human